Overview

A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia

Status:
Completed

Trial end date:
2000-12-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to compare the effectiveness and safety of a long-acting injectable formulation of risperidone (an antipsychotic medication) versus placebo for the treatment of the symptoms of schizophrenia over a 12-week period.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen, LP

Treatments:

Risperidone